Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BLQZY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LMB-164
|
|||||
| Synonyms |
LMB 164; SS1-dsFv-ABD-LRggs
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
|
|||||
| Antibody Name |
Anti-MSLN scFv
|
Antibody Info | ||||
| Antigen Name |
Mesothelin (MSLN)
|
Antigen Info | ||||
| Payload Name |
Pseudomonas exotoxin PE24
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic elongation factor 2 (EEF2)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 78.15
|
%
|
SW48 cells
|
Colon adenocarcinoma
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.38
|
ng/mL
|
KLM-1 cells
|
Pancreatic ductal adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 78.15% (Day 6) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.38 ng/mL±0.08 ng/mL | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.